Shares of BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) fell 2.3% during trading on Monday . The stock traded as low as $0.39 and last traded at $0.40. 380,070 shares were traded during trading, an increase of 20,345% from the average session volume of 1,859 shares. The stock had previously closed at $0.41.
BriaCell Therapeutics Stock Performance
The company has a market cap of $306,406.80, a PE ratio of 0.00 and a beta of 1.09. The business’s 50-day moving average is $0.65 and its 200 day moving average is $0.72.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Articles
- Five stocks we like better than BriaCell Therapeutics
- How to Invest in Biotech Stocks
- Sizing Up a New Opportunity for NVIDIA Investors
- Why Are Stock Sectors Important to Successful Investing?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- The Risks of Owning Bonds
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
